Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Non-Small Cell Lung Cancer (NSCLC): Update Bulletin #1 [November 2018]

Product Code:
596201042
Publication Date:
November 2018
Format:
PDF
Price:
£1,140

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from the US on a variety of recent events in the non-small cell lung cancer (NSCLC) market. KOLs provide their candid insights on key events, including:  the FDA approval of Merck & Co.’s Keytruda (pembrolizumab), in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of metastatic squamous NSCLC; the FDA approval of Pfizer's Vizimpro (dacomitinib) for the first-line treatment of EGFR-mutated NSCLC; Roche’s release of interim data from the IMpower-132 study of Tecentriq (atezolizumab) in combination with pemetrexed, and either carboplatin or cisplatin, in the first-line treatment of metastatic nonsquamous NSCLC.

Business Questions:

• How do KOLs react to the US approval of Merck & Co.’sKeytruda plus carboplatin with paclitaxel or nab-paclitaxel in the first-line treatment of squamous NSCLC?
• To what extent will Keytruda plus chemotherapy be incorporated into the first-line treatment of squamous NSCLC in the US?
• How do KOLs view the US approval of Pfizer's Vizimpro (dacomitinib) for the first-line treatment of EGFR-mutated NSCLC, and the ARCHER 1050 trial upon which it was based?
• What role is Vizimpro likely to play in the treatment of EGFR-mutated NSCLC in the US and do KOLs have any concerns regarding its use?
• According to KOLs, how does Vizimpro compare with AstraZeneca’s Tagrisso as a therapy for EGFR-mutated NSCLC?
• How do KOLs interpret the interim data released from the IMpower-132 study of Roche’s Tecentriq in combination with chemotherapy, in the first-line treatment of metastatic nonsquamous NSCLC?
• What are the chances of Tecentriq/chemotherapy being able to compete with Keytruda/chemotherapy in the first-line setting, and is there anything that could improve its prospects?




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved